Irmola Tero, Reito Aleksi, Kangas Jarmo, Eskelinen Antti, Niemeläinen Mika, Mattila Ville M, Moilanen Teemu
Coxa Hospital for Joint Replacement, Tampere, Finland.
Coxa Hospital for Joint Replacement, Tampere; Department of Orthopaedics and Trauma, Tampere University Hospital, Tampere, Finland.
Acta Orthop. 2025 Jan 24;96:127-134. doi: 10.2340/17453674.2024.42708.
The introduction and development of new total knee arthroplasty (TKA) implant designs are industry driven. To date, an adequately powered randomized controlled trial (RCT) to provide evidence of the superiority of novel implant designs over conventional ones is often lacking. The aim of our RCT was to investigate the functional outcomes of a novel TKA implant design compared with 2 conventional TKA designs. Primary outcome was difference in the change in Oxford Knee Score (OKS) at 2 years. Secondary outcomes were Forgotten Joint Score, 15D quality of life questionnaire, UCLA activity score, and complications.
We compared functional outcomes between a novel TKA implant design (Persona CR) and 2 conventional designs (NexGen CR, PFC CR). 240 patients with severe knee osteoarthritis were recruited to a pragmatic, single-center, prospective, parallel-group RCT between September 2015 and August 2018. The duration of follow-up was 2 years.
Of 240 randomized patients, 225 were included in the intention-to-treat analysis (mean age 61.8 years; 67.5% females). The OKS exceeded minimal clinical important difference (MCID) from baseline to 2 years in all 3 treatment groups (Persona CR: 18.9 points, PFC CR: 20.3 points, NexGen CR: 19.4 points). At 2 years the difference between Persona CR and PFC CR in the change score was -1.0 (95% confidence interval [CI] -3.6 to 1.7). Similarly, the difference between Persona CR and NexGen CR was -0.9 (CI -3.6 to 1.9). At the time of final follow-up evaluation, OKS was equivalent between groups, as CI excluded between-group differences larger than 4 points.
We showed no clinically relevant differences in functional outcomes measured with OKS, 15D, or FJS between the 2 conventional implant designs and the novel implant design at 2-year follow-up.
新型全膝关节置换术(TKA)植入物设计的引入和发展是由行业推动的。迄今为止,往往缺乏一项有足够效力的随机对照试验(RCT)来证明新型植入物设计优于传统设计。我们这项RCT的目的是研究一种新型TKA植入物设计与两种传统TKA设计相比的功能结局。主要结局是2年时牛津膝关节评分(OKS)变化的差异。次要结局包括遗忘关节评分、15D生活质量问卷、加州大学洛杉矶分校活动评分和并发症。
我们比较了一种新型TKA植入物设计(Persona CR)与两种传统设计(NexGen CR、PFC CR)之间的功能结局。2015年9月至2018年8月期间,240例重度膝关节骨关节炎患者被纳入一项实用、单中心、前瞻性、平行组RCT。随访时间为2年。
在240例随机分组的患者中,225例纳入意向性分析(平均年龄61.8岁;67.5%为女性)。在所有3个治疗组中,从基线到2年时OKS均超过最小临床重要差异(MCID)(Persona CR:18.9分,PFC CR:20.3分,NexGen CR:19.4分)。2年时,Persona CR与PFC CR在变化评分上的差异为-1.0(95%置信区间[CI]-3.6至1.7)。同样,Persona CR与NexGen CR之间的差异为-0.9(CI -3.6至1.9)。在最终随访评估时,各治疗组间OKS相当,因为CI排除了组间差异大于4分的情况。
我们发现在2年随访时,两种传统植入物设计与新型植入物设计在通过OKS、15D或FJS测量的功能结局方面无临床相关差异。